Page 4 of 13
Needle-free IPV boosts coverage, reduces costs
PharmaJet’s Tropis ID needle-free delivery system for fractional IPV (fIPV) administration increased second-dose IPV coverage by 11% compared to full-dose intramuscular administration, according to results from a Nigeria-based implementation study.
November 1, 2024
PharmaJet Announces Implementation Study Results: Increased Coverage, Cost Savings, and Preference for Routine Polio Immunization with Tropis® ID Needle-free Delivery
GOLDEN, Colo. — October 24, 2024 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free technology, today announced the results of an implementation study in Nigeria that evaluated the impact on coverage, costs, and acceptability of intradermal fractional inactivated poliovirus vaccine (fIPV) administration using their Tropis® ID Needle-free System, compared to the standard of care (full-dose, IPV intramuscular delivery with needle and syringe).
October 18, 2024
Improving Vaccine Performance using PharmaJet Needle-free Precision Delivery Technologies: World Vaccine Congress Europe Presentation
GOLDEN, Colo. — October 17, 2024 — PharmaJet® , a company that strives to improve the performance and outcomes of injectables with its enabling technology, today announced that they will share their latest research results at the World Vaccine Congress – Europe on October 29, 2024 at 1:40 pm GMT. The presentation, entitled Improving Performance of Vaccines with Needle-free Technology will be presented by Nathalie Landry, Chief Scientific Officer, PharmaJet.
Tags: Cancer, Events, Infectious Diseases, Tropis/Stratis
October 14, 2024
Dr. Wouter Latour joins PharmaJet as Chief Executive Officer
GOLDEN, Colo. — October 2, 2024 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling technology, today announced that Wouter Latour, M.D., has joined the company as Chief Executive Officer (CEO). Latour also joins the PharmaJet board of directors. He succeeds Chris Cappello who has recently been elected Vice-Chairman of the Board and will remain active in the business, largely focused on strategic partners and supporting engineering/operations.
Tags: Other
October 1, 2024
PharmaJet and Scancell Sign Strategic Partnership Agreement for Development and Commercialization of a Needle-free DNA Vaccine for Advanced Melanoma
GOLDEN, Colo. — September 17, 2024 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling technology, today announced that it has entered into a long-term license and supply agreement with Scancell Holdings plc (LSE – SCLP.L) to use the US FDA 510(k)-cleared / CE-marked PharmaJet Stratis® Intramuscular (IM) Needle-free System for the delivery of its advanced melanoma DNA vaccine (Immunobodysup>® SCIB1/iSCIB1+).
Tags: Melanoma, Other, Stratis
September 16, 2024
PharmaJet Needle-free System Selected for WHO Polio Immunization Campaign in Somalia
GOLDEN, Colo. — June 27, 2024 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its innovative delivery systems, today announced that their Tropis® Intradermal (ID) Needle-free System will be used in a house-to-house polio immunization campaign. With an aim of significantly reducing the immunity gap against type-2 poliovirus, the campaign will be conducted in two rounds. In each round, children 4-59 months of age will receive the needle-free polio vaccine and novel oral polio vaccine with a goal of achieving 95% coverage. The campaign, a collaboration of the African Field Epidemiology Network (AFENET), WHO, UNICEF, BMGF, GAVI and CDC, is targeting over 170,000 children in 4 districts in Banadir, Somalia.
June 20, 2024
Use of a fractional dose of inactivated polio vaccine (fIPV) to increase IPV coverage among children under 5 years of age in Somalia
2024 Nouh, K et al Use of a fractional dose of inactivated polio vaccine (fIPV) to increase IPV coverage among children under 5 years of age in Somalia
Tags: Inactivated, Polio, Tropis
June 13, 2024
An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial
2024 Saraf, A An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial
Tags: COVID-19, mRNA, Phase 2/3, Tropis
April 24, 2024
Nature Publication Highlights the Benefits of Tropis® Intradermal When Used to Administer a First-in-Class Self-Amplifying mRNA Vaccine
GOLDEN, Colo. — April 24, 2024 — PharmaJet®, a company that strives to improve the performance and outcomes of medicines with its innovative delivery systems, today announced the Nature publication of Gennova Biopharmaceutical’s Phase 2/3 clinical trial conducted to evaluate the safety and immunogenicity of its novel samRNA-based Covid-19 vaccine booster. The results demonstrated that GEMCOVAC-OM, administered exclusively with Tropis, is well-tolerated with no related serious adverse events and significantly boosts immune responses against the Omicron variant. Furthermore, the publication cited that the self-amplifying, thermostable mRNA platform delivered intradermally with Tropis provides a framework for next-generation vaccines that can improve accessibility and global equity.
PharmaJet Announces Scientific Advisory Boards and Presentation at World Vaccine Congress in Washington on April 1
GOLDEN, Colo. — April 1, 2024 —PharmaJet®, a company that strives to improve the performance and outcomes of medicines with its innovative delivery systems, today announced the formation of two Scientific Advisory Boards (SAB) comprised of leading pharmaceutical industry experts in immunology, cancer, research, and policy shaping. The Boards will provide strategic guidance and expertise to help PharmaJet advance its vision to better activate the immune system with its unique technology and accelerate its partnering strategy with vaccine and pharmaceutical companies.
Tags: Other, Tropis/Stratis
March 17, 2024
Notes from the Field: House-to-House Campaign Administration of Inactivated Poliovirus Vaccine — Sokoto State, Nigeria, November 2022
2023 | Biya, M., MD et al
December 4, 2023
First Human Clinical Study to Assess U.S. Department of Defense DNA Vaccine Candidate against Venezuelan Equine Encephalitis Delivered with PharmaJet Precision Delivery Systems.
GOLDEN, Colo. — November 16, 2023 — PharmaJet®, a company that has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced the start of the first human clinical trial for a Venezuelan Equine Encephalitis (VEE) vaccine delivered with PharmaJet Precision Delivery Systems. The Phase 1 study, sponsored by PharmaJet, aims to identify the optimal dose, vaccination schedule and delivery system most suitable for use in subsequent broader clinical evaluations of the VEE DNA vaccine candidate.
Tags: DNA, Nucleic Acid, Tropis/Stratis, VEEV
November 12, 2023
Daicel Group Invests in PharmaJet
GOLDEN, Colo. — October 31, 2023 — PharmaJet®, a company that engineers precision delivery systems that overcome the challenges of vaccines and pharmaceuticals delivery, today announced that it received a strategic investment from the Daicel Corporation. This investment coincides with Daicel’s announcement of the establishment of a new company, Daicel Medical Ltd., and reinforces Daicel’s commitment to growth in this critical area of healthcare.
Tags: Other, Tropis/Stratis
October 25, 2023
Partner With Us
Accelerate Your Product to Market with Needle-free Delivery With PharmaJet’s commercialized products and our technical and clinical expertise, you can progress rapidly from pre-clinical data into successful phase 1, 2 and 3 studies. 35+ Development Partners 50+ Active Studies in Progress 80+ Studies Completed See our full list of publications Strategic Alliances with...
October 20, 2023
PharmaJet, Nigeria’s National Primary Health Care Development Agency, and Health-focused Consortium Begin Implementation of Study Using Tropis® ID for Routine Immunization
GOLDEN, Colo. — October 24, 2023 — PharmaJet® , a company that engineers precision delivery systems that overcome the challenges of vaccines and pharmaceuticals delivery, today announced the implementation of a study in Nigeria to evaluate the impact of intradermal vaccine administration of fractional inactivated poliovirus vaccine (fIPV) using their Tropis® ID Needle-free Injection System (NFIS). The study, in collaboration with the National Primary Health Care Development Agency (NPHCDA), Jhpiego , PATH and the Sydani Group, is assessing coverage rates, and the potential for reduced costs, associated with using Tropis for fIPV delivery, as compared to the current standard of intramuscular delivery of full dose IPV using needle and syringe. Partners are also evaluating the acceptability and feasibility of using needle-free from the healthcare worker and caregiver perspective.
PharmaJet Partner, Scancell, Announces Positive Data from the First Stage of its Phase 2 Trial of Advanced Melanoma DNA Vaccine delivered Needle-free
GOLDEN, Colo. — September 28, 2023 — PharmaJet®, a company that engineers precision delivery systems that overcome the challenges of vaccines and pharmaceuticals delivery, today announced that its partner, Scancell, has received positive data from the first stage in its Phase 2 clinical study for treatment of patients with unresectable advanced melanoma. The vaccine is delivered by needle-free injection with the PharmaJet Stratis® System, which patients prefer over needle and syringe delivery.
Tags: DNA, Melanoma, Nucleic Acid, Stratis
September 26, 2023
Former Pfizer Vaccine Executive Nanette Cocero joins the PharmaJet Board of Directors.
GOLDEN, Colo. — July 11, 2023 – PharmaJet®, a company engineering Precision Delivery Systems™ that overcome the challenges of vaccines and pharmaceuticals delivery today announced that Nanette Cocero, Ph.D., has been appointed to its Board of Directors. Dr. Cocero is a recognized leader in the global pharmaceutical industry with broad commercial and business experience coupled with an extensive clinical and scientific background.
Tags: Other
July 8, 2023
India’s First mRNA-Based Omicron Booster Vaccine Gets DGCI Approval
The Drugs Controller General of India (DCGI) has granted Emergency Use Authorisation (EUA) to India’s first mRNA-based Omicron booster vaccine, and it is likely to be rolled out in 2-3 weeks, Gennova Biopharmaceuticals announced on Tuesday.
Tags: COVID-19, Gennova, mRNA, Nucleic Acid, Tropis
June 27, 2023
India’s 1st mRNA Omicron booster vax gets DCGI nod, to launch in 2-3 weeks
The Pune-based firm’s GemCovac-OM is a monovalent needle-free booster shot. It will be delivered intradermally with the PharmaJet Tropis Precision Delivery System (PDS) to adults of 18 years of age and older
Tags: COVID-19, Gennova, mRNA, Nucleic Acid, Tropis
PharmaJet Tropis Intradermal Delivery System is Now Authorized for Two Nucleic Acid Vaccines.
GOLDEN, Colo. — June 28, 2023 – PharmaJet®, a company engineering precision delivery systems that overcome challenges of nucleic acid vaccine delivery, today announced that its Tropis® System is now the exclusive intradermal delivery system for two authorized novel Covid-19 vaccines:
Page 4 of 13